Search Result

Isoforms Recommended:	BChE

Results for "

BuChE

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (4) Acyltransferase (1) Amyloid-β (15) Bacterial (4) Beta-secretase (3) Cholinesterase (ChE) (68) Complement System (1) COX (1) Drug Intermediate (2) Drug Metabolite (1) Endogenous Metabolite (1) ERK (2) FAAH (1) GABA Receptor (1) GSK-3 (1) Histamine Receptor (1) Interleukin Related (5) Isotope-Labeled Compounds (1) JNK (1) Monoamine Oxidase (4) nAChR (1) NF-κB (1) NO Synthase (1) NOD-like Receptor (NLR) (1) Opioid Receptor (1) p38 MAPK (2) Potassium Channel (4) Prostaglandin Receptor (1) Reactive Oxygen Species (ROS) (2) Reference Standards (4) Sodium Channel (4) Tau Protein (1) TNF Receptor (2) Toll-like Receptor (TLR) (1)
By Research Areas:	Cancer (4) Cardiovascular Disease (1) Endocrinology (1) Inflammation/Immunology (7) Metabolic Disease (3) Neurological Disease (70)
Click Chemistry:	Azide (1) Alkynes (1)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0034

Donepezil Hydrochloride Maximum Cited Publications 24 Publications Verification E2020	Cholinesterase (ChE)	Neurological Disease Cancer
Donepezil Hydrochloride (E2020) is a reversible, selective AChE inhibitor with an IC₅₀ of 6.7 nM for AChE activity. Donepezil shows high selectivity for AChE over BuChE . Donepezil exhibits neuroprotective effect on Aβ42 neurotoxicity .

HY-131922

Iso-OMPA Tetraisopropyl pyrophosphoramide	Cholinesterase (ChE)	Neurological Disease
Iso-OMPA (Tetraisopropyl pyrophosphoramide) is a selective inhibitor of the irreversible butyrylcholinesterase (BuChE). Iso-OMPA enhances soman toxicity in rats associated with the inhibition of plasma carboxylesterase (CarbE) .

HY-N0740

Jatrorrhizine chloride 3 Publications Verification	Cholinesterase (ChE) 5-HT Receptor Bacterial	Neurological Disease Inflammation/Immunology
Jatrorrhizine chloride is an alkaloid isolated from?Coptis chinensis with neuroprotective, antimicrobial, antiplasmodial and antioxidant activities . Jatrorrhizine chloride is a potent and orally active inhibitor of?AChE?(IC₅₀=872 nM) over >115-fold selectivity for BuChE . Jatrorrhizine chloride reduces uptake of serotonin (5-HT) and norepinephrine (NE) via inhibition of uptake-2 transporters .

HY-E70362

Butyrylcholinesterase (BCHE), Horse Serum BCHE, BuChE, PCHE, pseudocholinesterase, plasma cholinesterase, Acylcholine acyl-hydrolase, Choline esterase, butyryl	Others	Others
Butyrylcholinesterase (BCHE), Horse Serum (BCHE, BuChE, PCHE, pseudocholinesterase, plasma cholinesterase, Acylcholine acyl-hydrolase, Choline esterase, butyryl) is a biological material or organic compound that can be used in life science research .

HY-N0631

Cornuside Maximum Cited Publications 6 Publications Verification	p38 MAPK NF-κB JNK Cholinesterase (ChE) Acyltransferase NO Synthase Interleukin Related TNF Receptor Prostaglandin Receptor ERK COX	Neurological Disease Inflammation/Immunology
Cornuside is an iridoid glycoside with anti-allergic, anti-inflammatory, and neuroprotective activities. Cornuside exerts anti-allergic activity by downregulating the p38 MAPK, JNK, and NF-κB signaling pathways, and inhibits IgE-mediated histamine release from mast cells. Cornuside improves cognitive impairment in mice by inhibiting BACE1 activity (IC₅₀ = 55.84 μg/mL) and enhancing ChAT activity. Cornuside inhibits LPS (HY-D1056)-induced inflammatory mediators, including iNOS, COX-2, PGE2, TNF-α, IL-6, and IL-1β, by suppressing NF-κB activation .

HY-W027553

Ipidacrine NIK-247 free base; Amiridine free base	Cholinesterase (ChE) Potassium Channel Sodium Channel	Neurological Disease Metabolic Disease
Ipidacrine is orally active and brain-penetrant AChE and *BuChE* inhibitors with IC₅₀ values of 1 μM and 1.9 μM, respectively, which is also a partial agonist of M2-cholinergic receptors and a reversible cholinesterase inhibitor. Ipidacrine has a stimulating effect on neuromuscular transmission and excitation along the nerve fibres with a moderately anti-pain effect. Ipidacrine is an aminopyridines and is structurally similar to Tacrine (HY-111338). Ipidacrine is effective in various amnesia models, improves erectile function and inhibits K ⁺ and Na ⁺-channels in the neuronal membrane in diabetic rats. Ipidacrine is promising for research of Alzheimer’s disease, ischaemic stroke, idiopathic neuropathy of the facial nerve, diabetes mellitus-induced erectile dysfunction and other deficits in central or peripheral cholinergic deseases .

HY-N0749

Jatrorrhizine	Cholinesterase (ChE) 5-HT Receptor Bacterial	Neurological Disease
Jatrorrhizine is an alkaloid isolated from Coptis chinensis with neuroprotective, antimicrobial, antiplasmodial and antioxidant activities . Jatrorrhizine is a potent and orally active inhibitor of AChE (IC₅₀=872 nM) over >115-fold selectivity for BuChE . Jatrorrhizine reduces uptake of serotonin (5-HT) and norepinephrine (NE) via inhibition of uptake-2 transporters .

HY-N0749A

Jatrorrhizine hydroxide 3 Publications Verification	Cholinesterase (ChE) 5-HT Receptor Bacterial	Neurological Disease Inflammation/Immunology
Jatrorrhizine hydroxide is an alkaloid isolated from Coptis chinensis with neuroprotective, antimicrobial, antiplasmodial and antioxidant activities . Jatrorrhizine hydroxide is a potent and orally active inhibitor of AChE (IC₅₀=872 nM) over >115-fold selectivity for BuChE . Jatrorrhizine hydroxide reduces uptake of serotonin (5-HT) and norepinephrine (NE) via inhibition of uptake-2 transporters .

HY-153433

Serine Hydrolase inhibitor-21	Cholinesterase (ChE)	Neurological Disease
Serine Hydrolase inhibitor-21 (compound 8), a pyridine, is a serine hydrolase inhibitor with a K_i of 429 nM for BuChE. Serine Hydrolase inhibitor-21 has the potential for Alzheimer's disease research .

HY-131922R

Iso-OMPA (Standard) Tetraisopropyl pyrophosphoramide (Standard)	Cholinesterase (ChE) Reference Standards	Neurological Disease
Iso-OMPA (Standard) is the analytical standard of Iso-OMPA. This product is intended for research and analytical applications. Iso-OMPA (Tetraisopropyl pyrophosphoramide) is a selective inhibitor of the irreversible butyrylcholinesterase (BuChE). Iso-OMPA enhances soman toxicity in rats associated with the inhibition of plasma carboxylesterase (CarbE) .

HY-B0034S

Donepezil-d5 hydrochloride E2020-d₅	Cholinesterase (ChE)	Neurological Disease
Donepezil-d₅ (hydrochloride) is deuterium labeled Donepezil (Hydrochloride). Donepezil Hydrochloride (E2020) is a reversible, selective AChE inhibitor with an IC₅₀ of 6.7 nM for AChE activity. Donepezil shows high selectivity for AChE over BuChE . Donepezil exhibits neuroprotective effect on Aβ42 neurotoxicity .

HY-150003

Aβ1–42 aggregation inhibitor 1	Cholinesterase (ChE) Amyloid-β	Neurological Disease
Aβ1-42 aggregation inhibitor 1 inhibits AChE (acetylcholinesterase) and *BuChE* (butyrylcholinesterase) with the IC₅₀ value of 2.64 μM and 1.29 μM, respectively. Aβ1-42 aggregation inhibitor 1 inhibits self-mediated Aβ1-42 aggregation by 51.29% at a concentration of 25 μM. Aβ1-42 aggregation inhibitor 1 has the potential for the research of anti-Alzheimer's disease .

HY-151562

*AChE/BuChE/MAO-B-IN-1*	Cholinesterase (ChE) Monoamine Oxidase	Neurological Disease
AChE/BuChE/MAO-B-IN-1 (compound 19) is an inhibitor of human acetyl- (hAChE), butyrylcholinesterase (hBuChE) and monoamine oxidase-B (hMAO-B) with IC₅₀s of 4.8 μM, 13.7 μM, and 1.11 μM, respectively. AChE/BuChE/MAO-B-IN-1 also exhibits high affinity to both the σ₁ and σ₂ receptors with K_i values of 42.8 nM (human σ₁ receptor) and 191 nM (rat σ₂ receptor), respectively. AChE/BuChE/MAO-B-IN-1 can be used for Alzheimer’s disease research .

HY-144446

BuChE-IN-1	Cholinesterase (ChE)	Neurological Disease
BuChE-IN-1 (Compound 23) is a potent inhibitor of butyrylcholinesterase (BuChE). Butyrylcholinesterase (BuChE) is recently regarded as a biomarker in progressed Alzheimer’s disease (AD). BuChE-IN-1 shows low cytotoxicity and high blood brain barrier (BBB) permeability. BuChE-IN-1 is a promising BuChE inhibitor for the research of AD .

HY-115650

TAE-1	Cholinesterase (ChE) Amyloid-β	Neurological Disease
TAE-1 is a potent inhibitor of AChE and *BuChE*. TAE-1 also inhibits Aβ fibril formation and aggregation. TAE-1 can be used for the researches of Alzheimer's disease .

HY-B0034S1

Donepezil-d4 hydrochloride E2020-d₄	Cholinesterase (ChE)	Neurological Disease
Donepezil-d₄ (hydrochloride) is the deuterium labeled Donepezil hydrochloride. Donepezil Hydrochloride (E2020) is a reversible, selective AChE inhibitor with an IC₅₀ of 6.7 nM for AChE activity. Donepezil shows high selectivity for AChE over BuChE . Donepezil exhibits neuroprotective effect on Aβ42 neurotoxicity .

HY-117710B

AD-35	Cholinesterase (ChE) Amyloid-β ERK TNF Receptor Interleukin Related	Neurological Disease
AD-35 is an orally active anti-Alzheimer's disease (AD) agent with moderate AChE inhibitory activity and metal ion chelating ability. AD-35 exhibits IC₅₀ values for AChE and BuChE of 793 nM and 31428 nM, respectively. AD-35 can form chelates with Cu²⁺ and Fe³⁺, but its chelating ability for Zn²⁺ is relatively weak. AD-35 can inhibit Aβ aggregation and disassemble the formed Aβ aggregates, and inhibit Aβ-induced ERK phosphorylation. AD-35 inhibits neuroinflammation in AD rat models and demonstrates a strong effect in improving cognitive function .

HY-168563

BuChE-IN-15	Cholinesterase (ChE) FAAH	Neurological Disease
BuChE-IN-15 (compound D12) is a selective *BuChE/FAAH* dual inhibitor with and show IC₅₀ values of 81 and 400 nM for hBuChE and hFFAH, respectively. BuChE-IN-15 possesses good BBB penetration, and shows neuroprotection.BuChE-IN-15 can be used for study of Alzheimer .

HY-146142

*AChE/BuChE-IN-2*	Cholinesterase (ChE) Amyloid-β	Neurological Disease
AChE/BuChE-IN-2 (Compound 5f) is an orally active AChE and *BuChE* inhibitor with IC₅₀ values of 0.72 μM and 0.16 μM, respectively. AChE/BuChE-IN-2 shows a non-competitive inhibition with AChE and shows potent self-induced β-amyloid (Aβ) aggregation inhibition with an IC₅₀ of 62.52 μM. AChE/BuChE-IN-2 can cross the BBB .

HY-114320

BuChE-IN-TM-10 TM-10	Cholinesterase (ChE)	Neurological Disease
BuChE-IN-TM-10 (TM-10) is a potent butyrylcholinesterase (BuChE) inhibitor, with an IC₅₀ of 8.9 nM. BuChE inhibitor 1 inhibits and disaggregates self-induced Aβ aggregation, exhibiting potent antioxidant activity and good blood-brain barrier (BBB) penetration. Has potential to treat Alzheimer’s disease .

HY-121072

ASS234	Monoamine Oxidase Cholinesterase (ChE)	Neurological Disease
ASS234 is a potent monoamino oxidase (MAO) inhibitor with IC₅₀s of 5.2 nM and 43 nM for MAO-A and MAO-B, respectively. ASS234 also inhibits AChE and *BuChE* with IC₅₀s of 350 nM and 460 nM, respectively .

HY-162277

BuChE-IN-10	Cholinesterase (ChE)	Neurological Disease
BuChE-IN-10 (compound 7p) is an inhibitor of *BuChE* (eqBuChE IC₅₀ = 4.68 nM, huBuChE IC₅₀ = 9.12 nM). BuChE-IN-10 has anti-neuroinflammatory activity and exhibits high BBB permeability .

HY-155304

BuChE-IN-8	Cholinesterase (ChE)	Neurological Disease
BuChE-IN-8 (compound 19c) is a butyrylcholinesterase (BuChE) inhibitor with an IC₅₀ of 559 nM. BuChE-IN-8 possesses human β-secretase (BACE1) and Aβ40 aggregation inhibitory activities. BuChE-IN-8 has significant antiamnesic properties .

HY-146686

BuChE-IN-3	Cholinesterase (ChE)	Neurological Disease
BuChE-IN-3 (Compound C4) is a potent inhibitor of *BuChE* with an IC₅₀ of 8.3 nM. BuChE-IN-3 exhibits mild antioxidant capacity, nontoxicity, lipophilicity and neuroprotective activity .

HY-146687

BuChE-IN-4	Cholinesterase (ChE)	Neurological Disease
BuChE-IN-4 (Compound C6) is a potent inhibitor of *BuChE* with an IC₅₀ of 7.7 nM. BuChE-IN-4 exhibits mild antioxidant capacity, nontoxicity, lipophilicity and neuroprotective activity .

HY-162671

BuChE-IN-12	Cholinesterase (ChE)	Neurological Disease
BuChE-IN-12 is a selective *BuChE* inhibitor (IC₅₀=0.52 µM) that acts via affecting CAS and PAS sites and has potential effects against oxidative stress. BuChE-IN-12 can be used in the study of Alzheimer's disease .

HY-143413

BuChE-IN-2	Amyloid-β	Neurological Disease Inflammation/Immunology
BuChE-IN-2 is an excellent butyrylcholinesterase (BuChE) inhibitor (IC₅₀s of 1.28 μM and 0.67 μM for BuChE and NO). BuChE-IN-2 can inhibit the aggregation of Aβ, ROS formation and chelate Cu ²⁺, exhibiting proper blood-brain barrier (BBB) penetration. BuChE-IN-2 has potential to research Alzheimer’s disease .

HY-172782

BuChE-IN-20	Cholinesterase (ChE) Amyloid-β Interleukin Related Reactive Oxygen Species (ROS) NOD-like Receptor (NLR)	Neurological Disease Inflammation/Immunology
BuChE-IN-20 is a selective butyrylcholinesterase (hBuChE) inhibitor (IC₅₀ = 0.13 μM) with BBB permeability. BuChE-IN-20 is a L-Tryptophan derivative. BuChE-IN-20 possesses neuroprotective properties by inhibiting the production of nitric oxide (NO) and lowering the levels of ROS. BuChE-IN-20 is proficient in inhibiting the self-aggregation of amyloid-beta (Aβ) peptides. BuChE-IN-20 can be used in research for Alzheimer’s disease .

HY-W027553R

Ipidacrine (Standard) NIK-247 free base (Standard); Amiridine free base (Standard)	Reference Standards Cholinesterase (ChE) Potassium Channel Sodium Channel	Neurological Disease Metabolic Disease
Ipidacrine (Standard) is the analytical reference standard of Ipidacrine. This product is used for research and analytical applications. Ipidacrine is orally active and blood-brain-barrier-penetrant AChE and *BuChE* inhibitors with IC₅₀ values of 1 μM and 1.9 μM, respectively, which is also a partial agonist of M2-cholinergic receptors and a reversible cholinesterase inhibitor. Ipidacrine has a stimulating effect on neuromuscular transmission and excitation along the nerve fibres with a moderately anti-pain effect. Ipidacrine is an aminopyridines and is structurally similar to Tacrine (HY-111338). Ipidacrine is effective in various amnesia models, improves erectile function and inhibits K ⁺ and Na ⁺-channels in the neuronal membrane in diabetic rats. Ipidacrine is promising for research of Alzheimer’s disease, ischaemic stroke, idiopathic neuropathy of the facial nerve, diabetes mellitus-induced erectile dysfunction and other deficits in central or peripheral cholinergic deseases .

HY-144392

*AChE/BuChE-IN-1*	Cholinesterase (ChE)	Neurological Disease
AChE/BuChE-IN-1 (Compound 1), a chrysin derivative, is a selective butyrylcholinesterase (BuChE) inhibitor with an IC₅₀ of 0.48 μM. AChE/BuChE-IN-1 inhibits acetylcholinesterase (AChE) with an IC₅₀ of 7.16 μM. AChE/BuChE-IN-1 shows strong scavenging ·OH activities with a IC₅₀ of 0.1674 μM. AChE/BuChE-IN-1 inhibits reactive oxygen species (ROS), Aβ_1-42 aggregation (self-, Cu₂₊-induced, AChE-induced). AChE/BuChE-IN-1 has high BBB permeability and bioavailability and low cell toxicity. AChE/BuChE-IN-1 has the potential for Alzheimer' disease (AD) research .

HY-119292

AP2238	Cholinesterase (ChE) Amyloid-β	Neurological Disease
AP2238 is a dual-function acetylcholinesterase (AChE) inhibitor with K_i values for human AChE (HuAChE) and butyrylcholinesterase (BuChE) of 21.7 and 48.9 μM respectively. AP2238 blocks the pro-fibrotic interaction between the peripheral site of AChE and Aβ, and can inhibit Aβ aggregation. AP2238 can be used for the research of Alzheimer's disease .

HY-W856819

Eseroline	Opioid Receptor Cholinesterase (ChE) Drug Metabolite nAChR	Neurological Disease
Eseroline is a potent μ-opioid receptor agonist, which is the hydrolytic metabolite of Physostigmine (HY-N6608). Eseroline is a selective and competitive acetylcholinesterase (AChE) inhibitor, with its K_i values for AChE and BuChE being 0.1 μM and 200 μM respectively. Eseroline has nicotinic acetylcholine receptor allosteric enhancing ligand (nAChR-APL) activity, meaning it does not activate the receptor but significantly enhances the signal transduction of Ach triggered by the receptor. Eseroline is neurotoxic, causing cell membrane damage (LDH leakage) and energy metabolism collapse (ATP depletion). Eseroline can be used for the study of Alzheimer's disease .

HY-159133

BuChE-IN-13	Cholinesterase (ChE)	Neurological Disease
BuChE-IN-13 (compound 3) is a *BuChE* inhibitor and shows anti-Alzheimer activity. BuChE-IN-13 can be used for study of neurodegenerative disease .

HY-150585

BuChE-IN-5	Amyloid-β Cholinesterase (ChE) Tau Protein	Neurological Disease
BuChE-IN-5 (compound 25b) is a potent *BuChE* inhibitor with an IC₅₀ value of 1.94 μM. BuChE-IN-5 efficiently inhibits aggregation Aβ and tau protein in Escherichia coli. BuChE-IN-5 also has free radical scavenging capacity and antioxidant activity. BuChE-IN-5 can be used for researching Alzheimer’s disease .

HY-173486

BuChE-IN-21	Cholinesterase (ChE)	Neurological Disease Inflammation/Immunology
BuChE-IN-21 (compound SXF3) is a potent and selective *BuChE* inhibitor. BuChE-IN-21 inhibits eqBuChE and hBuChE with IC₅₀s of 0.05 and 0.04 μM, respectively. BuChE-IN-21 has high anti-inflammatory activity .

HY-155305

BuChE-IN-9	Cholinesterase (ChE) Beta-secretase GABA Receptor	Neurological Disease
BuChE-IN-9 (compound 22a) is a potent *equine serum-derived BuChE* (eqBuChE) inhibitor with an IC₅₀** of 173 nM. BuChE-IN-9 also inhibits human BACE1, Aβ aggregation, mouse GABA transporter 1 (mGAT1) and mGAT4. BuChE-IN-9 has significant antiamnesic properties .

HY-163746

BuChE-IN-11	Cholinesterase (ChE)	Neurological Disease
BuChE-IN-11 (Compound 3b-1) is an selective *BuChE* inhibitor with an IC₅₀ of 0.44 μM for hBuChE. BuChE-IN-11 has high blood-brain barrier permeability and exhibits strong antioxidant activity due to its free radical scavenging properties. BuChE-IN-11 interacts with the choline binding site, acetyl binding site, and peripheral anionic site, exhibiting submicromolar *BuChE* inhibitory activity and preventing β-amyloid (Aβ) self-aggregation. BuChE-IN-11 holds promise for research in the field of Alzheimer's disease .

HY-146251

BuChE-IN-6	Cholinesterase (ChE) Amyloid-β	Neurological Disease
BuChE-IN-6 (compound 1b) is a potent and selective *BuChE* (butyrylcholinesterase) inhibitor, with IC₅₀ values of 0.46 and 0.51 μM for eqBuChE and hBuChE, respectively. BuChE-IN-6 also inhibits Aβ₄₂ self-aggregation .

HY-147939

*AChE/BuChE-IN-3*	Cholinesterase (ChE) Amyloid-β	Cancer
AChE/BuChE-IN-3 is a potent and blood-brain barrier (BBB) penetrant AChE and *BuChE* dual inhibitor with IC₅₀s of 0.65 μM and 5.77 μM for AChE and BuChE. AChE/BuChE-IN-3 also inhibits Aβ_1-42 aggregation. AChE/BuChE-IN-3 has effectively neuroprotective activities and nearly no toxicity on SH-SY5Y cells. AChE/BuChE-IN-3 can be used for researching Alzheimer's disease .

HY-163537

*AChE/BuChE-IN-5*	Cholinesterase (ChE)	Neurological Disease
AChE/BuChE-IN-5 (compound 5a) is a dual target inhibitor. AChE/BuChE-IN-5 has excellent nanomolar inhibitory activity on acetylcholinesterase (AChE) (IC₅₀=46.9 nM) and butyryl cholinesterase (BuChE) (IC₅₀=3.5 nM). AChE/BuChE-IN-5 can be used for Alzheimer's Disease research .

HY-155349

*AChE/BuChE-IN-4*	Cholinesterase (ChE)	Neurological Disease
AChE/BuChE-IN-4(compound 4a) is a multitarget-directed *AChE/BuChE* inhibitor againstAChEandBuChE, with the IC₅₀ of 2.08 and 7.41 μM .

HY-170561

*AChE/BuChE-IN-6*	Cholinesterase (ChE)	Neurological Disease
AChE/BuChE-IN-6 (Compound 11f) is an inhibitor of AChE and *BuChE, with IC₅₀* values of 1.24 and 1.85 μg/mL, respectively. AChE/BuChE-IN-6 also exhibits strong DPPH free radical scavenging activity (IC₅₀ = 3.15 μg/mL). In vivo toxicity studies indicate that AChE/BuChE-IN-6 is safe, showing no significant differences in blood and biochemical markers compared to the control group after long-term administration, and no abnormalities were observed in liver and kidney tissues. AChE/BuChE-IN-6 holds promise for research into Alzheimer's disease .

HY-152632

BuChE-IN-7	Cholinesterase (ChE)	Neurological Disease
BuChE-IN-7 is a highly selective inhibitor of hBuChe and eqBuChE with IC₅₀ values of 40 nM, 80 nM respectively. BuChE-IN-7 can promote cognitive with blood-brain penetration and improves situational and phobic memory, showing preference for new things .

HY-149090

*AChE/BuChE/MAO-B-IN-2*	Cholinesterase (ChE) Monoamine Oxidase	Neurological Disease
AChE/BuChE/MAO-B-IN-2 (compound 4b) is a potent *AChE/BuChE* inhibitor and showed good blood brain barrier (BBB) permeability in vitro with an IC₅₀ value of 5.3 μM, 12.4 μM, 1.9±0.08 μM, for AChE, *BuChE, huMAO-B, respectively. AChE/BuChE/MAO-B-IN-2 (compound 4b) can inhibit excess AChE/BuChE* in Alzheimer's disease (AD) brain. AChE/BuChE/MAO-B-IN-2 (compound 4b) can be used in anti-Alzheimer's research .

HY-173621

Aβ1–42 aggregation inhibitor 3	Cholinesterase (ChE) Amyloid-β	Neurological Disease
Aβ1–42 aggregation inhibitor 3 (Compound 3b) is an acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) inhibitor (IC₅₀ values are 1.634 and 0.0285 μM, respectively). Aβ1–42 aggregation inhibitor 3 can inhibit the aggregation of Aβ_1-42. Aβ1–42 aggregation inhibitor can be used in Alzheimer's disease (AD) research .

HY-136813

Multitarget AD inhibitor-1	Beta-secretase Amyloid-β Cholinesterase (ChE)	Neurological Disease
Multitarget AD inhibitor-1 is a selective and reversible butyrylcholinesterase (BuChE) inhibitor with IC₅₀s of 7.22 μM and 1.55 μM for hBuChE and eqBuChE (BuChE from equine serum), respectively. Multitarget AD inhibitor-1 inhibits β-secretase (IC_50hBACE-1=41.60 μM), amyloid β aggregation (IC_50Aβ=3.09 μM), tau aggregation. Multitarget AD inhibitor-1, a diphenylpropylamine derivative, has the potential for multifunctional disease-modifying anti-Alzheimer’s research .

HY-150728

AChE-IN-22	Cholinesterase (ChE)	Neurological Disease
AChE-IN-22 (compound 10q) is a selective acetylcholinesterase (AChE) inhibitor against AChE and *BuChE* with the IC₅₀ values of 0.88 μM and 10 μM, respectively. AChE-IN-22 can bind to both the CAS (catalytic active site) and PAS (peripheral anionic site) of AChE and has the potential for the research of Alzheimer's disease .

HY-144388

ChE/Aβ1-42-IN-1	Cholinesterase (ChE) Amyloid-β	Neurological Disease
ChE/Aβ1-42-IN-1 (compound 28) is a potent ChE and Aβ_1-42 aggregation inhibitor with IC₅₀s of 0.062, 0.767 and 1.227 µM for AChE, BuChE and Aβ_1-42 aggregation, respectively. ChE/β1-42-IN-1 shows excellent BBB penetration. ChE/Aβ1-42-IN-1 is a potent multi-targeted anti-Alzheimer's agent .

HY-178141

*AChE/BuChE-IN-7*	Cholinesterase (ChE)	Neurological Disease
AChE/BuChE-IN-7 is a dual-action inhibitor with an IC₅₀ valueof 0.15 μM for AChE and 0.7 μM for *BuChE, SI of 4.7. AChE/BuChE-IN-7 shows anti-oxidant activity and can mitigate H₂O₂-induced cytotoxicity. AChE/BuChE-IN-7 has genomic stability and prolonged systemic availability. AChE/BuChE*-IN-7 can be used for the research of neurological disease, such as Alzheimer's disease .

HY-181503

*AChE/BuChE-IN-8*	Cholinesterase (ChE)	Neurological Disease Cancer
AChE/BuChE-IN-8 is a dual AChE and *BuChE* inhibitor, with an AChE IC₅₀ of 1.18 μM, a human AChE K_i of 1.2 μM, and a BuChE IC₅₀ of 2.34 μM. AChE/BuChE-IN-8 acts as an antiproliferative agent and antioxidant, exerts antiproliferative effects on colon cancer cells, scavenges free radicals, and exhibits reducing power. AChE/BuChE-IN-8 can be used in the research of Alzheimer's disease and colorectal adenocarcinoma .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0740

Jatrorrhizine chloride 3 Publications Verification	Alkaloids Monophenols Coptis chinensis Franch. Ranunculaceae Phenols Plants Isoquinoline Alkaloids Source Classification	Cholinesterase (ChE) 5-HT Receptor Bacterial
Jatrorrhizine chloride is an alkaloid isolated from?Coptis chinensis with neuroprotective, antimicrobial, antiplasmodial and antioxidant activities . Jatrorrhizine chloride is a potent and orally active inhibitor of?AChE?(IC₅₀=872 nM) over >115-fold selectivity for BuChE . Jatrorrhizine chloride reduces uptake of serotonin (5-HT) and norepinephrine (NE) via inhibition of uptake-2 transporters .

HY-N0631

Cornuside Maximum Cited Publications 6 Publications Verification	Structural Classification Iridoids Cornaceae Classification of Application Fields Cornus officinalis Sieb. et Zucc. Terpenoids Phenols Polyphenols Plants Inflammation/Immunology Disease Research Fields Source Classification	p38 MAPK NF-κB JNK Cholinesterase (ChE) Acyltransferase NO Synthase Interleukin Related TNF Receptor Prostaglandin Receptor ERK COX
Cornuside is an iridoid glycoside with anti-allergic, anti-inflammatory, and neuroprotective activities. Cornuside exerts anti-allergic activity by downregulating the p38 MAPK, JNK, and NF-κB signaling pathways, and inhibits IgE-mediated histamine release from mast cells. Cornuside improves cognitive impairment in mice by inhibiting BACE1 activity (IC₅₀ = 55.84 μg/mL) and enhancing ChAT activity. Cornuside inhibits LPS (HY-D1056)-induced inflammatory mediators, including iNOS, COX-2, PGE2, TNF-α, IL-6, and IL-1β, by suppressing NF-κB activation .

HY-N0749

Jatrorrhizine	Alkaloids Monophenols other families Phenols Plants Isoquinoline Alkaloids Source Classification	Cholinesterase (ChE) 5-HT Receptor Bacterial
Jatrorrhizine is an alkaloid isolated from Coptis chinensis with neuroprotective, antimicrobial, antiplasmodial and antioxidant activities . Jatrorrhizine is a potent and orally active inhibitor of AChE (IC₅₀=872 nM) over >115-fold selectivity for BuChE . Jatrorrhizine reduces uptake of serotonin (5-HT) and norepinephrine (NE) via inhibition of uptake-2 transporters .

HY-N0749A

Jatrorrhizine hydroxide 3 Publications Verification	Alkaloids Monophenols Coptis chinensis Franch. Ranunculaceae Phenols Plants Isoquinoline Alkaloids Source Classification	Cholinesterase (ChE) 5-HT Receptor Bacterial
Jatrorrhizine hydroxide is an alkaloid isolated from Coptis chinensis with neuroprotective, antimicrobial, antiplasmodial and antioxidant activities . Jatrorrhizine hydroxide is a potent and orally active inhibitor of AChE (IC₅₀=872 nM) over >115-fold selectivity for BuChE . Jatrorrhizine hydroxide reduces uptake of serotonin (5-HT) and norepinephrine (NE) via inhibition of uptake-2 transporters .

HY-N0740R

Jatrorrhizine chloride (Standard)	Alkaloids Monophenols Coptis chinensis Franch. Ranunculaceae Phenols Plants Isoquinoline Alkaloids Source Classification	Reference Standards Cholinesterase (ChE) 5-HT Receptor Bacterial
Jatrorrhizine (chloride) (Standard) is the analytical standard of Jatrorrhizine (chloride). This product is intended for research and analytical applications. Jatrorrhizine chloride is an alkaloid isolated from Coptis chinensis with neuroprotective, antimicrobial, antiplasmodial and antioxidant activities . Jatrorrhizine chloride is a potent and orally active inhibitor of AChE (IC50=872 nM) over >115-fold selectivity for BuChE . Jatrorrhizine chloride reduces uptake of serotonin (5-HT) and norepinephrine (NE) via inhibition of uptake-2 transporters .

HY-N11997

Feralolide	Liliaceae Coumarins Phenols Polyphenols Aloe vera (L.) Burm. f. Phenylpropanoids Plants Source Classification	Cholinesterase (ChE)
Feralolide is a dihydroisocoumarin isolated from the methanolic extract of aloe vera resin. Feralolide is also a dual inhibitor of AChE and BuChE, with IC₅₀s of 55 μg/mL and 52 μg/mL respectively. Feralolide has antioxidant activity and inhibits 2,2-diphenyl-1-picrylhydrazyl (DPPH) and 2, 2′-azinobis-3-ethylbenzothiazoline-6-sulfonic acid (ABTS). Feralolide could be used in research into cognitive disorders such as Alzheimer's disease, potentially restoring and enhancing memory .

Cat. No.	Product Name	Chemical Structure

HY-B0034S

Donepezil-d5 hydrochloride
Donepezil-d₅ (hydrochloride) is deuterium labeled Donepezil (Hydrochloride). Donepezil Hydrochloride (E2020) is a reversible, selective AChE inhibitor with an IC₅₀ of 6.7 nM for AChE activity. Donepezil shows high selectivity for AChE over BuChE . Donepezil exhibits neuroprotective effect on Aβ42 neurotoxicity .

HY-B0034S1

Donepezil-d4 hydrochloride
Donepezil-d₄ (hydrochloride) is the deuterium labeled Donepezil hydrochloride. Donepezil Hydrochloride (E2020) is a reversible, selective AChE inhibitor with an IC₅₀ of 6.7 nM for AChE activity. Donepezil shows high selectivity for AChE over BuChE . Donepezil exhibits neuroprotective effect on Aβ42 neurotoxicity .

HY-W027553S1

Ipidacrine-d9

Ipidacrine-d₉ (NIK-247-d₉ (free base)) is the deuterium labeled Ipidacrine (HY-W027553). Ipidacrine is orally active and brain-penetrant AChE and BuChE inhibitors with IC₅₀ values of 1 μM and 1.9 μM, respectively, which is also a partial agonist of M2-cholinergic receptors and a reversible cholinesterase inhibitor. Ipidacrine has a stimulating effect on neuromuscular transmission and excitation along the nerve fibres with a moderately anti-pain effect. Ipidacrine is an aminopyridines and is structurally similar to Tacrine (HY-111338). Ipidacrine is effective in various amnesia models, improves erectile function and inhibits K+ and Na+-channels in the neuronal membrane in diabetic rats. Ipidacrine is promising for research of Alzheimer’s disease, ischaemic stroke, idiopathic neuropathy of the facial nerve, diabetes mellitus-induced erectile dysfunction and other deficits in central or peripheral cholinergic deseases .

Cat. No.	Product Name		Classification

HY-121072

ASS234		Alkynes
ASS234 is a potent monoamino oxidase (MAO) inhibitor with IC₅₀s of 5.2 nM and 43 nM for MAO-A and MAO-B, respectively. ASS234 also inhibits AChE and *BuChE* with IC₅₀s of 350 nM and 460 nM, respectively .

HY-159133

BuChE-IN-13		Azide
BuChE-IN-13 (compound 3) is a *BuChE* inhibitor and shows anti-Alzheimer activity. BuChE-IN-13 can be used for study of neurodegenerative disease .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks